SB 649868

SB-649868 is a dual orexin receptor antagonist in development by GlaxoSmithKline. The drug is currently in phase II development for insomnia.

A phase I study evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects.

In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency. The subsequent study added a 60 mg dose and observed dose-dependent sleep promotion.